siRNA candidate enters the clinic

SR Pharma has launched a Phase I clinical trial of RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma.

RTP-801i is based on Atugen's proprietary siRNA technology that modifies the expression of one specific gene target involved in the progression of age-related macular degeneration (AMD).

Pfizer, who licensed the product in September of last year, is funding the trial.